Immunofluorescence analysis of HER-4 was done on 70% confluent log phase T47D cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were labeled with HER-4 (H4.77.16 (Ab77)) Mouse Monoclonal Antibody (MA512888) at 2ug/ml in 0.1% BSA and incubated for 3 hours at room temperature and then labeled with Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (Product # A28175) at a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (S36938). F-actin (Panel c: red) was stained with Alexa Fluor® 555 Rhodamine Phalloidin (Product # R415, 1:300). Panel d is a merged image showing cytoplasmic and membranous localization. Panel e is a no primary antibody control. The images were captured at 60X magnification.
|Tested species reactivity||Human, Mouse, Rat|
|Published species reactivity||Rat, Human, Mouse, Not Applicable|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Extracellular fragment of recombinant human c-erbB-4/HER-4 oncoprotein|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||0.5 ug/test|
|Immunoprecipitation (IP)||2µg/mg protein lysate|
|Western Blot (WB)||1:50-1:500|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-12888 targets HER-4 in Western blot, flow cytometry and immunoprecipitation applications and shows reactivity with Human, mouse, and Rat samples.
The MA5-12888 immunogen is extracellular fragment of recombinant human c-erbB-4/HER-4 oncoprotein.
c-erbB-4 is the fourth member of class I receptor kinase family (ErbB). Down regulation of ErbB-4 in estrogen receptor-positive cancer cells inhibits proliferation.
IP-MS enrichment of ERBB4 (Intensity): ERBB4 was enriched 1998-fold from HEK293 lysate compared to background proteins, using the optimized IP-MS workflow with Pierce MS-Compatible Magnetic IP Kit protein A/G (Part No. 90409) and ERBB4 antibody (Part No. MA5-12888). The STRING database (www.string-db.org) was used to identify the protein interactor list. See more information on IP-MS verification of antibody selectivity. IP-MS validation info.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Neuregulin 1 confers neuroprotection in SOD1-linked amyotrophic lateral sclerosis mice via restoration of C-boutons of spinal motor neurons.
MA5-12888 was used in immunohistochemistry to study neuroprotection in SOD1-linked amyotrophic lateral sclerosis mice via restoration of C-boutons of spinal motor neurons by Neuregulin 1
|Lasiene J,Komine O,Fujimori-Tonou N,Powers B,Endo F,Watanabe S,Shijie J,Ravits J,Horner P,Misawa H,Yamanaka K||Acta neuropathologica communications (4:null)||2016|
Immunohistochemical analysis of the monoclonal antibody 4B5 in breast tissue expressing human epidermal growth factor receptor 4 (HER4).
MA5-12888 was used in immunohistochemistry to study the utility of the 4B5 monoclonal antibody for clinical HER2 status determination in breast tissue expressing HER4
|Jay JI,Brunhoeber PS,Smith MH,Williams RR,Sugarman MC,Free HL,Tast DE||Histopathology (62:563)||2013|
Gene expression and immunolocalization of heparin-binding epidermal growth factor-like growth factor and human epidermal growth factor receptors in human corpus luteum.
MA5-12888 was used in immunohistochemistry to study the expression and immunolocalization of HB-EGF-like growth factor and EGFR in human corpus luteum
|Akayama Y,Takekida S,Ohara N,Tateiwa H,Chen W,Nakabayashi K,Maruo T||Human reproduction (Oxford, England) (20:2708)||2005|
Regulation of ErbB-4 endocytosis by neuregulin in GABAergic hippocampal interneurons.
MA5-12888 was used in immunocytochemistry to study the role of neuregulin in modulating ErbB4 endocytosis in cultured hippocampal neurons
|Longart M,Chatani-Hinze M,Gonzalez CM,Vullhorst D,Buonanno A||Brain research bulletin (73:210)||2007|
Isolation of scFvs to in vitro produced extracellular domains of EGFR family members.
MA5-12888 was used in ELISA to develop and characterize specific antibodies targeting EGFR family
|Horak E,Heitner T,Robinson MK,Simmons HH,Garrison J,Russeva M,Furmanova P,Lou J,Zhou Y,Yuan QA,Weiner LM,Adams GP,Marks JD||Cancer biotherapy and radiopharmaceuticals (20:603)||2005|
HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization.
MA5-12888 was used in flow cytometry to study the role of HER-2/neu overexpression in increasing the viable hypoxic cell population within solid tumors
|Dragowska WH,Warburton C,Yapp DT,Minchinton AI,Hu Y,Waterhouse DN,Gelmon K,Skov K,Woo J,Masin D,Huxham LA,Kyle AH,Bally MB||Molecular cancer research : MCR (2:606)||2004|
Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer.
MA5-12888 was used in flow cytometry to investigate the status of the endothelial cell growth, cell death and fibrosis in aggressive inflammatory breast cancer
|Shirakawa K,Tsuda H,Heike Y,Kato K,Asada R,Inomata M,Sasaki H,Kasumi F,Yoshimoto M,Iwanaga T,Konishi F,Terada M,Wakasugi H||Cancer research (61:445)||2001|
Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol.
MA5-12888 was used in flow cytometry to study the role of the HER-2 receptor in modulating the response of ovarian cancer cells to doxorubicin, cisplatin and taxol
|Aigner A,Hsieh SS,Malerczyk C,Czubayko F||Toxicology (144:221)||2000|
Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2.
MA5-12888 was used in flow cytometry to investigate the synergistic inhibitory effect of anti-HER2 antibody and anti-oestrogen on breast cancer cells
|Kunisue H,Kurebayashi J,Otsuki T,Tang CK,Kurosumi M,Yamamoto S,Tanaka K,Doihara H,Shimizu N,Sonoo H||British journal of cancer (82:46)||2000|